Drug intelligence / Profile preview

ECP-101

Development stage: Preclinical
Lead developer: ECP
Modality: Small Molecules

Overview

ECP-101 is a small molecule drug candidate being developed by ECP Pharma for the treatment of mild traumatic brain injury (mTBI). The drug is derived from cannabinoids and psychedelic compounds, though its specific molecular targets have not been publicly disclosed. ECP-101 is designed to promote rapid recovery from mTBI and mitigate the risk of long-term neurological consequences, such as dementia and Alzheimer's disease. It is currently in the IND-enabling phase of development and represents ECP Pharma's most advanced program.

Beyond the preview

Go deeper on ECP-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECP-101.

Explore the full profile